Analyst rating accuracy & track record
Charles Duncan is an equity research analyst at Cantor Fitzgerald. Bullish Whales has scored 27 of their stock calls across 15 companies. Their picks beat their sector 42% of the time over the next 12 months, and their price targets were reached 31% of the time within a year.
Track record
Bullish Whales has scored 27 of Charles Duncan's stock calls across 15 companies, dating back to 2020. Their rated stocks beat their own sector 42% of the time over the next 12 months. On a typical call, a Duncan pick returned −6.0% more than its sector over the following year.
Of the scored calls, 27 were bullish (Buy). Most of their coverage sits in Healthcare. Every number on this page is an estimate from our own data. It is for education only and is not investment advice.
Coverage & ratings
Ratings & price targets
| Stock | Rating | Price target | Rated | 12-mo vs sector | PT hit |
|---|---|---|---|---|---|
 CMPSCompass Pathways Plc | Buy | — | Mar 2025 | +83.0% | — |
 BHVNBiohaven Ltd. | Buy | — | Oct 2024 | −68.4% | — |
| BHVNBiohaven Ltd. | Buy | — | Oct 2024 | −67.1% | — |
| BHVNBiohaven Ltd. | Buy | — | Sep 2024 | −63.1% | — |
 VNDAVanda Pharmaceuticals Inc | Buy | $13.00 | Aug 2024 | −10.8% | Miss |
| VNDAVanda Pharmaceuticals Inc | Buy | $11.00 | Jul 2024 | −12.7% | Miss |
 ATAIATAI Life Sciences BV | Buy | — | Jun 2024 | +52.9% | — |
| ATAIATAI Life Sciences BV | Buy | — | Apr 2024 | −42.5% | — |
 CPRXCatalyst Pharmaceuticals Inc | Buy | $34.00 | Mar 2024 | +59.3% | Miss |
| CPRXCatalyst Pharmaceuticals Inc | Buy | $34.00 | Mar 2024 | +29.5% | Miss |
| CPRXCatalyst Pharmaceuticals Inc | Buy | $34.00 | Mar 2024 | +29.7% | Miss |
 CRNXCrinetics Pharmaceuticals Inc | Buy | $50.00 | Oct 2023 | +84.4% | Hit |
 NBIXNeurocrine Biosciences Inc | Buy | — | Oct 2023 | −14.4% | — |
 DNLIDenali Therapeutics Inc | Buy | $35.00 | Oct 2023 | +12.0% | Miss |
| CPRXCatalyst Pharmaceuticals Inc | Buy | $27.00 | Aug 2023 | +27.1% | Miss |
 BIVIBiovie Inc | Buy | $11.00 | Aug 2023 | −108.1% | Miss |
 CRDLCardiol Therapeutics Inc Class A | Buy | $3.00 | Aug 2023 | +109.1% | Hit |
| CPRXCatalyst Pharmaceuticals Inc | Buy | $27.00 | Aug 2023 | +18.3% | Miss |
 VXRTVaxart Inc | Buy | $4.00 | Aug 2023 | −27.4% | Miss |
| BIVIBiovie Inc | Buy | $11.00 | May 2023 | −106.5% | Miss |
 FENCFennec Pharmaceuticals Inc | Buy | $12.00 | Nov 2022 | −4.4% | Miss |
| BIVIBiovie Inc | Buy | $7.00 | Jul 2022 | +96.6% | Hit |
 NEUPNeuphoria Therapeutics Inc | Buy | $52.00 | Jan 2022 | −63.9% | Miss |
| CRDLCardiol Therapeutics Inc Class A | Buy | $8.00 | Dec 2021 | −70.7% | Miss |
 INOInovio Pharmaceuticals Inc | Buy | $45.00 | Jun 2020 | −100.1% | Miss |
 TVRDTvardi Therapeutics, Inc. | Buy | $34.00 | Apr 2020 | +46.9% | Miss |
| INOInovio Pharmaceuticals Inc | Buy | $13.00 | Apr 2020 | −9.9% | Hit |
Charles Duncan: analyst track record FAQ
Is Charles Duncan a good stock analyst?
Yes, by track record. Charles Duncan ranks number 165 of 347 of the analysts Bullish Whales scores, with a BW Score of 32 out of 100. Past results do not guarantee future ones.
What is Charles Duncan's win rate?
Charles Duncan's win rate is 42%. Across 27 scored calls, their rated stocks beat their sector 42% of the time over the next 12 months. On a typical call they returned −6.0% more than the sector.
What stocks and sectors does Charles Duncan cover?
Charles Duncan covers 15 companies, with the most coverage in Healthcare. See the ratings table above for every scored call and its outcome.
Are Charles Duncan's price targets accurate?
Charles Duncan's price targets are reached within 12 months 31% of the time. The base rate across all analysts Bullish Whales tracks is about 43 percent.
How accurate are Wall Street analyst price targets?
Most analyst price targets are not reached on schedule. Across every target Bullish Whales scores, the stock reaches the target within 12 months only about 43 percent of the time, which is why it helps to compare hit rates analyst by analyst.
Should I follow Charles Duncan's stock ratings?
Their track record is strong, but no analyst is right every time. Follow the long-term track record rather than any single rating, size your positions to your own risk, and treat this as research, not investment advice.
How does Bullish Whales score analyst accuracy?
Bullish Whales scores every rating on real prices. We enter at the closing price on or after the call date, with no look-ahead, then measure the 12-month return above the stock's sector ETF and check whether the price target was reached. Scores are pulled toward the population average and corrected for testing thousands of analysts at once, so they reflect repeatable skill rather than luck.
How does Charles Duncan rank among Wall Street analysts?
Charles Duncan ranks number 165 of 347 by BW Score. We rank analysts by their realized 12-month sector-excess return and require a minimum number of calls so a few lucky picks cannot reach the top.
Browse the full analyst leaderboardHow analyst accuracy is scored
Every score, Win %, PT Hit % and rank is an estimate Bullish Whales calculates from its own data and may not be 100% accurate or complete. Returns are measured in excess of each rated stock's own sector over the 12 months after each call. Past performance does not guarantee future results, and nothing here is a recommendation to buy or sell any security.